Meet our Trustee: Simon Keightley
Simon spent 40 years as a consultant ophthalmic surgeon at the North Hampshire Hospital in Basingstoke.
Search
Search results
Applications invited for project grants and studentships
Retina UK invites applications for funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease. We are particularly keen to receive proposals with demonstrable translational potential.
Look Forward – Summer 2025 – Issue 186
This edition marks the start of the charity's 50th anniversary year. It includes lots of ways to get involved over the next 12 months along with details of our Annual and Professionals' Conferences in September.
e-Newsletter – May 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Look Forward – Winter 2025 – Issue 188
This is the final edition of Look Forward this year and what a year it has been! We’ve had some very positive feedback about our Conferences and the Big Give Christmas Challenge is back - a great opportunity to double your donation at no extra cost to you! We’ve included a handy ‘What’s on’ article which outlines some of our plans for 2026. We would like to take this opportunity to wish all of our readers a very Merry Christmas and a happy and fulfilling New Year.
Online information & support
Retina UK has a number of online support resources which we offer via social media.
Types of inherited sight loss
Inherited progressive sight loss is caused by a range of rare genetic conditions. We specialise in those which affect the retina.
Diagnosis and beyond
Making yourself aware of the what you are entitled to, and understanding the diagnosis pathway for inherited sight loss, will put you in a stronger position to seek better support.
Webinar: Visual hallucinations and Charles Bonnet syndrome
Prof Dominic Ffytche will provide an explanation of what Charles Bonnet Syndrome is, the science behind it, and share some potential coping strategies for people who experience visual hallucinations.
FAQs: Luxturna (voretigene neparvovec)
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.